Payne SL, Anandakumaran PN, Varga BV, Morshead CM, Nagy A, Shoichet MS. (2018) Tissue Eng Part A. 2018 Feb;24(3-4):351-360. doi: 10.1089/ten.TEA.2016.0515. Epub 2017 Jul 11. PMID: 28594288
Führmann T, Anandakumaran PN, Payne SL, Pakulska MM, Varga BV, Nagy A, Tator C, Shoichet MS.(2018) Biomed Mater. 2018 Feb 2;13(2):024103. doi: 10.1088/1748-605X/aa96dc. PMID: 29083317
Liang Q, Monetti C, Shutova MV, Neely EJ, Hacibekiroglu S, Yang H, Kim C, Zhang P, Li C, Nagy K, Mileikovsky M, Gyongy I, Sung HK, Nagy A. (2018) Nature. 2018. Nov 21; 563(7733): 701-704 PMID: 30429614
Payne SL, Tuladhar A, Obermeyer JM, Varga BV, Teal CJ, Morshead CM, Nagy A, Shoichet MS (2019). Biomaterials. 2019 Feb;192:309-322. doi:10.1016/j.biomaterials.2018.11.020. Epub 2018 Nov 15. PMID: 30468998
Ross PJ, Zhang WB, Mok RSF, Zaslavsky K, Deneault E, D’Abate L, Rodrigues DC, Yuen RKC, Faheem M, Mufteev M, Piekna A, Wei W, Pasceri P, Landa RJ, Nagy A, Varga B, Salter MW, Scherer SW, Ellis J.(2020) Biol Psychiatry. 2020 Jan 15;87(2):139-149. doi: 10.1016/j.biopsych.2019.07.014. Epub 2019 Jul 29. PMID: 31540669 Free PMC article.
Synaptic Dysfunction in Human Neurons With Autism-Associated Deletions in PTCHD1-AS Read More »
Islam R, Drecun S, Varga BV, Vonderwalde I, Siu R, Nagy A and Morshead CM (2021) Front. Cell. Neurosci. 15:654290. doi:10.3389/fncel.2021.654290
Pluristyx, Inc. and Stem
Genomics SAS today announce the closing of an equity investment and strategic partnership in Stem Genomics. Through the partnership, the companies will offer a unified pathway to allow customers to evaluate the genomic stability of Pluristyx’s pluripotent stem cell (PSC) lines using Stem Genomics’ iCS-digital™ PSC assay.
Pluristyx, Inc. today announced an agreement with the
Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and
commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs).
This collaboration will make it possible to accelerate the scalable, consistent, and cost-effective
manufacturing of stem cell derived products for patient administration.
The partnership will improve access to clinical-grade genetically-modified induced pluripotent stem cells June 12, 2023 – Seattle – Pluristyx and panCELLa, a merged biotechnology company with offices in Seattle, WA and Toronto, Ontario, CA, are excited to announce their acceptance as an Industry Resource Partner (IRP) with the California Institute for Regenerative Medicine (CIRM). This
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, talks to Pharma’s Almanac about pluripotent stem cells and how the company speeds up the R&D process by delivering Ready to Differentiate® cells.
The Next Big Thing in Pharma Read More »
